Orthotopic heart transplantation in patients with treated malignancies

Daniel J. Goldstein, J. Alex Seldomridge, Linda Addonizio, Eric A. Rose, Mehmet C. Oz, Robert E. Michler

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

The accumulated data suggest that carefully selected patients with a history of treated neoplasms and end-stage cardiac failure can expect satisfactory survival and little risk of recurrence and new-onset malignancy after transplantation. An optimal disease-free interval is difficult to estimate; the current experience suggests that it should be based on the histology and clinical stage of the disease at the time of diagnosis and treatment. The incidence of post-transplant infectious complications, rejection episodes, and coronary artery disease has been reported in only a few patients.6 Extreme caution must be exercised before transplantation is considered for patients with a history of clinically or histologically unfavorable tumors. Continued follow-up and further clinical experience is eagerly awaited to confirm these encouraging preliminary findings.

Original languageEnglish (US)
Pages (from-to)968-971
Number of pages4
JournalThe American Journal of Cardiology
Volume75
Issue number14
DOIs
StatePublished - May 1 1995
Externally publishedYes

Fingerprint

Heart Transplantation
Transplantation
Neoplasms
Coronary Artery Disease
Histology
Heart Failure
Transplants
Recurrence
Survival
Incidence
Therapeutics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Orthotopic heart transplantation in patients with treated malignancies. / Goldstein, Daniel J.; Seldomridge, J. Alex; Addonizio, Linda; Rose, Eric A.; Oz, Mehmet C.; Michler, Robert E.

In: The American Journal of Cardiology, Vol. 75, No. 14, 01.05.1995, p. 968-971.

Research output: Contribution to journalArticle

Goldstein, Daniel J. ; Seldomridge, J. Alex ; Addonizio, Linda ; Rose, Eric A. ; Oz, Mehmet C. ; Michler, Robert E. / Orthotopic heart transplantation in patients with treated malignancies. In: The American Journal of Cardiology. 1995 ; Vol. 75, No. 14. pp. 968-971.
@article{4045d9ffb5ed47288da73f2fbe8de9cf,
title = "Orthotopic heart transplantation in patients with treated malignancies",
abstract = "The accumulated data suggest that carefully selected patients with a history of treated neoplasms and end-stage cardiac failure can expect satisfactory survival and little risk of recurrence and new-onset malignancy after transplantation. An optimal disease-free interval is difficult to estimate; the current experience suggests that it should be based on the histology and clinical stage of the disease at the time of diagnosis and treatment. The incidence of post-transplant infectious complications, rejection episodes, and coronary artery disease has been reported in only a few patients.6 Extreme caution must be exercised before transplantation is considered for patients with a history of clinically or histologically unfavorable tumors. Continued follow-up and further clinical experience is eagerly awaited to confirm these encouraging preliminary findings.",
author = "Goldstein, {Daniel J.} and Seldomridge, {J. Alex} and Linda Addonizio and Rose, {Eric A.} and Oz, {Mehmet C.} and Michler, {Robert E.}",
year = "1995",
month = "5",
day = "1",
doi = "10.1016/S0002-9149(99)80704-8",
language = "English (US)",
volume = "75",
pages = "968--971",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "14",

}

TY - JOUR

T1 - Orthotopic heart transplantation in patients with treated malignancies

AU - Goldstein, Daniel J.

AU - Seldomridge, J. Alex

AU - Addonizio, Linda

AU - Rose, Eric A.

AU - Oz, Mehmet C.

AU - Michler, Robert E.

PY - 1995/5/1

Y1 - 1995/5/1

N2 - The accumulated data suggest that carefully selected patients with a history of treated neoplasms and end-stage cardiac failure can expect satisfactory survival and little risk of recurrence and new-onset malignancy after transplantation. An optimal disease-free interval is difficult to estimate; the current experience suggests that it should be based on the histology and clinical stage of the disease at the time of diagnosis and treatment. The incidence of post-transplant infectious complications, rejection episodes, and coronary artery disease has been reported in only a few patients.6 Extreme caution must be exercised before transplantation is considered for patients with a history of clinically or histologically unfavorable tumors. Continued follow-up and further clinical experience is eagerly awaited to confirm these encouraging preliminary findings.

AB - The accumulated data suggest that carefully selected patients with a history of treated neoplasms and end-stage cardiac failure can expect satisfactory survival and little risk of recurrence and new-onset malignancy after transplantation. An optimal disease-free interval is difficult to estimate; the current experience suggests that it should be based on the histology and clinical stage of the disease at the time of diagnosis and treatment. The incidence of post-transplant infectious complications, rejection episodes, and coronary artery disease has been reported in only a few patients.6 Extreme caution must be exercised before transplantation is considered for patients with a history of clinically or histologically unfavorable tumors. Continued follow-up and further clinical experience is eagerly awaited to confirm these encouraging preliminary findings.

UR - http://www.scopus.com/inward/record.url?scp=0028923637&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028923637&partnerID=8YFLogxK

U2 - 10.1016/S0002-9149(99)80704-8

DO - 10.1016/S0002-9149(99)80704-8

M3 - Article

VL - 75

SP - 968

EP - 971

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 14

ER -